As of Feb 17
| -0.26 / -0.15%|
The 7 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 124.00, with a high estimate of 229.00 and a low estimate of 95.00. The median estimate represents a -26.26% decrease from the last price of 168.16.
The current consensus among 11 polled investment analysts is to Hold stock in United Therapeutics Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.